Colorectal Cancer
Exact Sciences Releases Next-Gen Cologuard Data, Inks New Partnerships
The firm said the new version of its colon cancer screening test improved upon its predecessor across a variety of metrics, including both sensitivity and specificity.
Foundation Medicine Blood Test Gets FDA Approval as CDx for Pfizer's Braftovi in Colorectal Cancer
The FDA has approved the FoundationOne Liquid CDx assay to identify patients with BRAF V600E alterations eligible for treatment with Braftovi.
Large Study of Early-Onset Colorectal Cancer Patients IDs Unique, Potentially Actionable Mutations
In younger patients, HER2 mutations were more prevalent in those who had MSI-high/TMB-high tumors, while POLE mutations were more common in MSS/TMB-high tumors, researchers reported at ASCO.
Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Guardant Health Pushing Hard to Contextualize CRC Screening Data as Core Business Chugs Along
Premium
The company is seeing continuing growth for its existing clinical products as it moves resources toward commercialization of its Guardant Shield CRC screening test.